Technical Analysis for SCLP - Scancell Holdings Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 22.75 | 1.11% | 0.25 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Historical SCLP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Hammer Candlestick | Bullish | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 1.11% | |
| Bollinger Band Squeeze | Range Contraction | 1.11% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2% | 1 day ago |
| Down 1% | 1 day ago |
| Fell Below Lower Bollinger Band | 1 day ago |
Free Daily (Stock) Chart Reading
Scancell Holdings Plc Description
Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Biotechnology Medicine Clinic Pipe Cancer Branches Of Biology Medical Specialties Therapy Clinical Trial Biopharmaceutical Therapies Immunology Antibody Immune System Tumor Antibodies Vaccine Immunotherapy Lung Cancer Monoclonal Antibodies Cancer Therapeutics Treatment Of Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 29.0 |
| 52 Week Low | 4.85 |
| Average Volume | 2,016,603 |
| 200-Day Moving Average | 14.44 |
| 50-Day Moving Average | 22.03 |
| 20-Day Moving Average | 22.96 |
| 10-Day Moving Average | 22.94 |
| Average True Range | 1.50 |
| ADX | 19.97 |
| +DI | 19.48 |
| -DI | 14.49 |
| Chandelier Exit (Long, 3 ATRs ) | 20.51 |
| Chandelier Exit (Short, 3 ATRs ) | 26.49 |
| Upper Bollinger Band | 23.69 |
| Lower Bollinger Band | 22.23 |
| Percent B (%b) | 0.36 |
| BandWidth | 6.40 |
| MACD Line | 0.18 |
| MACD Signal Line | 0.33 |
| MACD Histogram | -0.1544 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 24.25 | ||||
| Resistance 3 (R3) | 24.17 | 23.58 | 24.00 | ||
| Resistance 2 (R2) | 23.58 | 23.20 | 23.63 | 23.92 | |
| Resistance 1 (R1) | 23.17 | 22.97 | 22.88 | 23.25 | 23.83 |
| Pivot Point | 22.58 | 22.58 | 22.44 | 22.63 | 22.58 |
| Support 1 (S1) | 22.17 | 22.20 | 21.88 | 22.25 | 21.67 |
| Support 2 (S2) | 21.58 | 21.97 | 21.63 | 21.58 | |
| Support 3 (S3) | 21.17 | 21.58 | 21.50 | ||
| Support 4 (S4) | 21.25 |
